| Similar Articles |
|---|
 |
The Motley Fool
August 17, 2010
Brian Orelli |
Forget About This Drug Saving the Company Lilly's Alzheimer's drug fails hard.   |
Chemistry World
October 14, 2009
Phil Taylor |
Tracing amyloid in Alzheimer's A diagnostic compound that allows researchers to look into the brains of Alzheimer's patients will be used for the first time to gauge the effects of an experimental therapy for the disease. |
Chemistry World
November 2009
Derek Lowe |
Column: In the pipeline The author advises opening your mind during the screening cascade taken by potential drug targets, and remaining goal orientated at all times |
Chemistry World
July 20, 2012
Michael Parkin |
New supramolecular Alzheimer's drugs Supramolecular chemistry could provide a new avenue in the treatment of Alzheimer's disease, say scientists in China. |
Chemistry World
July 3, 2014
Maria Burke |
Renewed focus on dementia checked by drug challenges The risks and barriers for companies working in dementia are huge, but so too, potentially, are the rewards, says Simon Ridley, head of research at Alzheimer's Research UK. |
The Motley Fool
August 4, 2010
Mac Greer |
One Biotech Stock Ready to Rebound? One of our analysts gives you his thoughts on Elan. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Alzheimer's: A Disease at a Crossroads The need for new drugs intensifies as more and more Baby Boomers live into advanced old age. The global market is estimated to be worth $20 billion by the end of the decade. |
Food Processing
March 2009
Diane Toops |
Kraft Foods Global Thinks Outside the Box with Bioactive Ingredients Kraft hires a pharmaceutical company to help it develop functional foods. |
AskMen.com
Jacob Franek |
Alzheimer's Disease 101 It's only in the last decade or so that we have truly come to understand the various disorders of the brain that are associated with age and, in most cases, Alzheimer's disease is the prime suspect. Read on for some basic information. |
Chemistry World
January 2010
Derek Lowe |
Column: In the pipeline I've recently marked my 20th year of drug discovery research, which prompted me to think about what has changed since I started work in the industry. |
The Motley Fool
September 5, 2008
Brian Lawler |
Why Pfizer Made an Interesting Blockbuster Bet The pharma giant inked a deal worth potentially more than $725 million with development stage drugmaker Medivation to market Medivation's Alzheimer's disease drug Dimebon. |
The Motley Fool
January 29, 2010
Brian Orelli |
How to Make Billions of Dollars Without Really Trying Lackluster Alzheimer's drugs have been doing it for years. |
Chemistry World
December 21, 2006
Tom Westgate |
Molecular Probe Identifies Patients at Risk of Alzheimer's A new molecule could provide an early warning system for Alzheimer's disease, US researchers hope. |
Chemistry World
July 30, 2008
Sarah Houlton |
A metal trap to stop Alzheimer's Trapping metals could prove a key to curing Alzheimer's disease, according to the promising results of early clinical trials on a compound called PBT2. |
Chemistry World
July 26, 2012
Derek Lowe |
Screen shots You might not think that the makeup of a compound screening collection could set off many arguments, but there are a few issues there that will do the trick almost every time. |
Chemistry World
February 27, 2009
Hayley Birch |
More data from mixtures via NMR Finnish scientists have developed a new technique for separating out the NMR spectra of compounds in a mixture. |
Chemistry World
May 2, 2012
Russell Johnson |
Reducing the cost of oxygen enrichment A simple synthesis using ionic liquids reduces the cost of studying micro-porous oxide materials by NMR. This could help scientists uncover the chemistry and interactions that occur inside these materials. |
Reactive Reports
October 2006
David Bradley |
Drink Up! Lest We Forget There is potentially good news for red wine lovers whose favorite tipple is Cabernet Sauvignon. Researchers have found that moderate consumption of Cabernet Sauvignon can attenuate neural degradation in laboratory mice with Alzheimer's disease. |
The Motley Fool
September 2, 2005
Rich Duprey |
An Opportunity Not to Forget Japanese pharmaceutical Eisai targets another segment of the growing Alzheimer's market. Investors, take note. |
Chemistry World
April 25, 2013
Andreas Barth |
Chemical bibliometrics Counting compounds instead of publications and citations opens new perspectives for data-based scientific discovery and it can complement and stimulate both experimental and theoretical research. |
Financial Planning
August 1, 2009
Donna Mitchell |
Alzheimer's Toll A study surveyed 369 advisors in the U.S. to gauge their understanding of Alzheimer's and their preparedness for dealing with clients who have the disease. |
AskMen.com
Jacob Franek |
Future Cures Almost every disease known to man is under constant research and we can hardly go a day without hearing about some advancement or another. Here are a few diseases for which future cures could be looming on the horizon. |
Chemistry World
October 28, 2014
Derek Lowe |
Chemical space is big. Really big. We are not going to run out of interesting and useful structures, and the uses that they could be put to are probably also beyond our imagining. In chemical space, we really do have an effectively endless frontier. |
The Motley Fool
February 8, 2005
Charly Travers |
Investing in a Cure Drugs in the pipeline offer potential breakthroughs for Alzheimer's disease. Instead of investing in small biotechs that have a lot riding on a single Alzheimer's program, the best way to invest in the field is through a diversified company |
